Newsfeeds - Spark Newswire

1 minute read

Mirati Therapeutics To Present New Research From Oncology Pipeline At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer

Today, 4:35 PM

https://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-new-research-from-its-innovative-oncology-pipeline-at-the-2021-aacr-nci-eortc-virtual-international-conference-on-molecular-targets-and-cancer-30139

MRTX

1 minute read

Analyst Ratings

What 6 Analyst Ratings Have To Say About Mirati Therapeutics

By Benzinga Insights

Today, 4:35 PM

Over the past 3 months, 6 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

MRTX

11 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 23, 2021

By Benzinga Insights

Today, 4:35 PM

AMGN

1 minute read

Stifel Initiates Coverage On Mirati Therapeutics with Buy Rating, Announces Price Target of $202

By Benzinga Newsdesk

Today, 4:35 PM

Stifel analyst Benjamin Burnett initiates coverage on Mirati Therapeutics (NASDAQ:MRTX) with a Buy rating and announces Price Target of $202.

MRTX

4 minute read

Options

9 Health Care Stocks Showing Unusual Options Activity In Today’s Session

By Benzinga Insights

Today, 4:35 PM

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.

CRVS

1 minute read

10 Biggest Price Target Changes For Tuesday

By Lisa Levin

Today, 4:35 PM

RBC Capital boosted MSCI Inc. (NYSE: MSCI) price target from $650 to $720. MSCI shares rose 1.6% to $645.00 in pre-market trading.

BIG

1 minute read

Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Raises Price Target to $173

By Benzinga Newsdesk

Today, 4:35 PM

Morgan Stanley analyst Michael Ulz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Equal-Weight and raises the price target from $160 to $173.

MRTX

1 minute read

Oppenheimer Maintains Perform on Mirati Therapeutics, Raises Price Target to $175

By vishwanath@benzinga.com

Today, 4:35 PM

Oppenheimer analyst Jay Olson maintains Mirati Therapeutics (NASDAQ:MRTX) with a Perform and raises the price target from $160 to $175.

MRTX

1 minute read

SVB Leerink Maintains Outperform on Mirati Therapeutics, Raises Price Target to $205

By Benzinga Newsdesk

Today, 4:35 PM

SVB Leerink analyst Andrew Berens maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $195 to $205.

MRTX

1 minute read

FDA
News

Why Mirati Therapeutics Stock Is Trading Higher Today

By Adam Eckert

Today, 4:35 PM

Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday after the company announced clinical data with investigational adagrasib as monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.

MRTX